Pricing Log in Create free account
Friday 6 November 2026 Export SEPN’s income statement to Excel — free account

Septerna, Inc.

SEPN Healthcare Biotechnology

Septerna, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $46.0 million, up 4,174.5% from fiscal 2024.

Revenue
+22,375.6%
EPS
+48.2%
Free cash flow
−9.01%

Quarter to June 2026, against a year earlier

48.95 1.60 +3.38%
Market cap
$2.2B
P/E
0.0×
Fwd P/E
−32.6×
Dividend yield
—
F-score
5/9
Altman Z
3.41
Beneish M
32.85
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Septerna, Inc. (SEPN) Debt to equity

Alert me on Debt to equity

Septerna, Inc.'s debt to equity at the end of the quarter to 30 June 2026 was 0.0×, down 0.0× from fiscal 2025 (0.0×). That is in line with the Biotechnology industry median of 0.0× and in line with the Healthcare sector median of 0.0×.

Debt to equity, annual

Embed this chart

Annual newest first

Period Debt to equity Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —

Quarterly newest first

Period Debt to equity Change
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
Sep 2025 0.0× —
7 more quarters

Debt to equity against peers

Company Debt to equity
BHVN Biohaven Ltd. compare −2.7×
PVLA Palvella Therapeutics, Inc. compare 0.0×
ZYME Zymeworks Inc. compare 0.0×
SEPN Septerna, Inc. 0.0×
VCEL Vericel Corporation compare 0.0×
IMNM Immunome, Inc. compare 0.0×
LKFT Lakefront Biotherapeutics - Sponsored ADR compare 0.0×
AUPH Aurinia Pharmaceuticals Inc compare 0.1×
VERA Vera Therapeutics, Inc. compare 0.2×
Biotechnology industry median 0.0×
Healthcare sector median 0.0×
Market median 0.1×

What Debt to equity is

Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.

(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)

The full definition of Debt to equity →

More on SEPN